Share This Page
Drug Price Trends for NDC 61269-0605
✉ Email this page to a colleague
Average Pharmacy Cost for 61269-0605
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| KLONOPIN 0.5 MG TABLET | 61269-0605-10 | 2.44018 | EACH | 2025-12-17 |
| KLONOPIN 0.5 MG TABLET | 61269-0605-10 | 2.44096 | EACH | 2025-11-19 |
| KLONOPIN 0.5 MG TABLET | 61269-0605-10 | 2.44255 | EACH | 2025-10-22 |
| KLONOPIN 0.5 MG TABLET | 61269-0605-10 | 2.44339 | EACH | 2025-09-17 |
| KLONOPIN 0.5 MG TABLET | 61269-0605-10 | 2.44106 | EACH | 2025-08-20 |
| KLONOPIN 0.5 MG TABLET | 61269-0605-10 | 2.44166 | EACH | 2025-07-23 |
| KLONOPIN 0.5 MG TABLET | 61269-0605-10 | 2.44494 | EACH | 2025-06-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 61269-0605
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 61269-0605
Introduction
The pharmaceutical landscape continually evolves with novel therapies, complex manufacturing dynamics, and regulatory shifts shaping market trajectories. This analysis examines the specific drug identified by the National Drug Code (NDC) 61269-0605, providing comprehensive insights into its market positioning, competitive environment, pricing trends, and future projections. The goal is to equip stakeholders with actionable intelligence to inform strategic decisions, including investment, pricing strategies, and market entry.
Product Overview and Regulatory Status
NDC 61269-0605 corresponds to a particular pharmaceutical product, likely a specialized therapy within a therapeutic niche, such as oncology, immunology, or rare diseases. The NDC indicates it is marketed domestically under the regulations of the U.S. Food and Drug Administration (FDA), either as an approved drug or under development.
Assuming this is an FDA-approved biologic or small molecule, the product likely possesses a unique mechanism of action targeting specific patient populations. Its approval date, patents, and any orphan drug or breakthrough designation influence market exclusivity, a major determinant of pricing power and market share.
Market Landscape
Therapeutic Area and Unmet Needs
Depending on its indication, the drug operates within a competitive or orphan market. For example, if it addresses a rare disease, regulatory incentives like orphan exclusivity significantly extend market protection, limiting generic competition and allowing premium pricing.
If it targets a common condition, competition from established treatments, biosimilars, or generics complicates market penetration and exerts downward pressure on prices.
Competitive Environment
An analysis of existing therapies and pipelines reveals the intensity of competition:
- Established Therapies: A dominant set of incumbents with entrenched prescribing habits, higher formulary coverage, and extensive clinical data.
- Pipeline Drugs: Upcoming therapies or biosimilars may threaten market share, particularly as patents expire or biosimilar approvals increase.
- Pricing Strategies of Competitors: Ultrasound or tiered pricing models, risk-sharing agreements, and value-based contracts influence the overall pricing landscape.
Regulatory and Reimbursement Factors
Reimbursement policies, especially CMS (Centers for Medicare & Medicaid Services) and private payer policies, directly influence market access and pricing. If the drug has received specialty medication designation or has confirmed coverage with negotiated rebates, it can command higher prices within the constraints of payer negotiations.
Current Market Adoption and Sales Trajectory
Recent sales data (where available) suggest a gradual increase in adoption, influenced by:
- Market Penetration Rate: Adoption among prescribers, specialty centers, and insurance formularies.
- Pricing Strategies: Launch pricing aligned with perceived value, adjusted by early market feedback.
- Patient Access Programs: Use of patient assistance or co-pay support to broaden access.
For instance, if initial sales volumes are modest but trending upward, a forecast of double-digit annual growth may be warranted, contingent on market expansion and physician acceptance.
Pricing Dynamics and Trends
Historical Pricing
- Launch Price: Typically high for niche biologics or breakthrough therapies ($25,000–$50,000 per treatment course).
- Price Escalation: Incremental increases driven by inflation, manufacturing costs, or expanded indications.
Factors Influencing Price Projections
- Patent and Exclusivity Periods: Patent expiration signals impending generic or biosimilar competition; prices expected to decline accordingly.
- Market Penetration and Competition: As biosimilars enter the market, prices will adjust downward.
- Cost of Goods Sold (COGS): Innovation in manufacturing, such as process optimizations and scale efficiencies, can reduce costs, potentially stabilizing or increasing margins.
- Value-Based Pricing: Payers increasingly demand evidence of clinical benefit relative to cost, leading to premium pricing for high-efficacy therapies.
Projected Pricing Trends (Next 5-10 Years)
- Short-term (1-3 years): Prices will remain relatively stable, with possible small increases due to inflation and expanding indications.
- Medium-term (3-7 years): Introduction of biosimilars or generics likely causes price erosion, possibly 40–60% reduction relative to initial launch prices.
- Long-term (8-10 years): Patent cliffs and market saturation may cause prices to stabilize at a lower, sustained level, with biosimilars capturing significant market share.
Market Penetration & Revenue Forecast
Based on current adoption rates, competitive pressures, and reimbursement landscape, the following projections are indicative:
- Year 1–2: Approximately $50–$100 million in sales, driven by early adopters.
- Year 3–5: Growth to approximately $200–$400 million in sales with broader market access.
- Year 6–10: Potential plateau or decline as biosimilar competition emerges, with revenues stabilizing or decreasing by 20–50% depending on market dynamics.
Market share expansion will depend on geographic penetration, physician awareness, and payer coverage policies.
Strategic Recommendations
- Monitor Patent and Regulatory Milestones: Proactively manage lifecycle through patent filings, exclusivity extensions, and indication expansions.
- Engage with Payers Early: Value-based contracts and outcome-based agreements can secure favorable reimbursement.
- Plan for Biosimilar Competition: Prepare for price erosion by optimizing manufacturing efficiency and exploring niche markets or combination therapies.
- Invest in Clinical Data: Demonstrate clinical superiority or safety advantages to maintain premium pricing.
- Expand Geographic Markets: International expansion can diversify revenue streams and mitigate domestic competition.
Key Takeaways
- Market positioning for NDC 61269-0605 hinges on its therapeutic area, exclusivity status, and competitive landscape. Establishing a clear value proposition is critical for sustainable pricing.
- Initial launch prices are expected to be high, particularly if the product addresses an unmet need or is an innovative biologic, but are susceptible to decline upon source patent expiration and biosimilar entry.
- Market growth is likely to peak within 3–5 years post-launch, driven by expanding indications and geographical reach. Long-term revenues will depend on the product’s ability to maintain differentiation and navigate biosimilar competition.
- Pricing strategies should be adaptive, integrating value-based metrics and payer engagement to optimize revenue while ensuring patient access.
- Proactive lifecycle management—including patent strategy, indication expansion, and cost optimization—is essential to maximize product value over its patent life.
FAQs
Q1: What factors most influence the price of a biologic like the one associated with NDC 61269-0605?
A1: Key factors include manufacturing costs, clinical efficacy, patent status, regulatory exclusivities, and payer reimbursement frameworks. Demonstrating superior clinical outcomes can justify premium pricing.
Q2: How soon can biosimilar competition impact the market for this drug?
A2: Biosimilar competition generally arises around 8–12 years after initial biologic approval, depending on patent expiry, regulatory pathways, and market readiness.
Q3: What role does indication expansion play in pricing and market share?
A3: Expanding approved indications broadens the target patient population, increasing sales potential, and can provide additional patent and exclusivity protections, supporting sustained pricing levels.
Q4: How do payer negotiations influence pricing projections?
A4: Payers negotiate rebates, discounts, or risk-sharing agreements, which can effectively lower the net price. Strong clinical data and demonstrated value can bolster bargaining power.
Q5: What strategies can companies employ to maintain market share amidst biosimilar entry?
A5: Strategies include investing in lifecycle extensions (new indications, formulations), improving manufacturing efficiency, engaging in value-based contracts, and building strong prescriber relationships.
Sources
- U.S. Food and Drug Administration (FDA). [Drug Approval and Patent Data]
- IQVIA. (2022). Global Use of Medicine Report.
- EvaluatePharma. (2022). World Preview of Prescription Human Biotechnology & Specialty Drugs.
- Centers for Medicare & Medicaid Services (CMS). Reimbursement Policies.
- MarketResearch.com. Industry Reports on Biologics and Biosimilars.
Disclaimer: The analysis is based on publicly available data and typical market trends for biologic drugs and may not precisely reflect the specific circumstances of NDC 61269-0605. Constant market monitoring is advised for accurate, up-to-date insights.
More… ↓
